VEGF inhibitor PTC299

Phase 1/2Terminated

1 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Kaposi's Sarcoma

Conditions

Kaposi's Sarcoma

Trial Timeline

Sep 1, 2008 → Dec 1, 2010

NCT ID

NCT00686842

About VEGF inhibitor PTC299

VEGF inhibitor PTC299 is a phase 1/2 stage product being developed by PTC Therapeutics for Kaposi's Sarcoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00686842. Target conditions include Kaposi's Sarcoma.

What happened to similar drugs?

1 of 1 similar drugs in Kaposi's Sarcoma were approved

Approved (1) Terminated (0) Active (0)

✅Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/TenofovirMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01158300	Phase 1	Completed	Nov 1, 2010	Jan 1, 2015	Brain and Central Nervous System Tumors
NCT00686842	Phase 1/2	Terminated	Sep 1, 2008	Dec 1, 2010	Kaposi's Sarcoma

Competing Products

5 competing products in Kaposi's Sarcoma

See all competitors

Product	Company	Stage	Hype Score
Selumetinib	AstraZeneca	Phase 1/2	24
Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir	Merck	Approved	43
Maraviroc	Pfizer	Phase 2	35
50 mg/m2 aldoxorubicin + 100 mg/m2 aldoxorubicin + 150 mg/m2 aldoxorubicin	ImmunityBio	Phase 2	32
Tc 99m tilmanocept	Navidea Biopharmaceuticals	Phase 2	25